{"latest_checked": "2026-07-31T22:10:54.858067+00:00", "coverage_count": 5078, "recent_count": 12, "transaction_limit": 160, "filters": {"q": "", "ticker": "AVTX", "sector": "", "industry": "", "side": "", "start": "2026-06-18", "end": "2026-08-02"}, "summary": {"total": 12, "acquisition_count": 7, "disposal_count": 5, "acquisition_value": 96230.07, "acquisition_value_label": "$96.2K", "disposal_value": 119180.0, "disposal_value_label": "$119.2K", "net_value": -22949.93, "net_value_label": "$-22.9K", "flow_tone": "negative", "largest_value_label": "$93.1K", "top_sector": "Healthcare", "window_label": "18 Jun 2026 to 02 Aug 2026"}, "charts": {"sectors": [{"ticker__sector": "Healthcare", "count": 12, "value": "215410.0700", "bar_width": 100.0, "sector_slug": "healthcare", "value_label": "$215.4K"}], "days": [{"transaction_date": "2026-06-23", "acquisitions": 2, "disposals": 2, "total": 4, "bar_width": 50.0}, {"transaction_date": "2026-06-30", "acquisitions": 5, "disposals": 3, "total": 8, "bar_width": 100.0}], "side_mix": {"acquisitions": 7, "disposals": 5, "acquisition_share": 58.3, "disposal_share": 41.7}}, "company_flows": [{"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "sector": "Healthcare", "industry": "Biotechnology", "sector_url": "https://sharemaestro.com/insider-activity/sectors/healthcare/", "industry_url": "https://sharemaestro.com/insider-activity/sectors/healthcare/industries/biotechnology/", "latest_transaction": "2026-06-30", "acquisitions": 7, "disposals": 5, "acquired_value": 96230.07, "acquired_value_label": "$96.2K", "disposed_value": 119180.0, "disposed_value_label": "$119.2K", "net_value": -22949.93, "net_value_label": "$-22.9K", "acquisition_share": 58.3, "disposal_share": 41.7, "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}], "company_overview": [{"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NASDAQ", "country": "US", "sector_url": "https://sharemaestro.com/insider-activity/sectors/healthcare/", "industry_url": "https://sharemaestro.com/insider-activity/sectors/healthcare/industries/biotechnology/", "latest_transaction": "2026-06-30", "filings": 12, "acquisitions": 7, "disposals": 5, "acquired_value": 96230.07, "acquired_value_label": "$96.2K", "disposed_value": 119180.0, "disposed_value_label": "$119.2K", "net_value": -22949.93, "net_value_label": "$-22.9K", "acquisition_share": 58.3, "disposal_share": 41.7, "tone": "Net acquisition", "tone_class": "positive", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}], "transactions": [{"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-30", "executive": "DOYLE, MITTIE", "executive_title": "Chief Medical Officer", "security_type": "Common Stock", "side_code": "D", "side": "Disposal", "shares": 4654.0, "share_price": 20.0, "transaction_value": 93080.0, "fetched_at": "2026-07-20T22:02:08.123623+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-30", "executive": "DOYLE, MITTIE", "executive_title": "Chief Medical Officer", "security_type": "Common Stock", "side_code": "A", "side": "Acquisition", "shares": 2875.0, "share_price": 12.65, "transaction_value": 36368.75, "fetched_at": "2026-07-20T22:02:08.126641+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-30", "executive": "LIND, KEVIN ROBERT", "executive_title": "Director", "security_type": "Stock Option (Right to Buy)", "side_code": "A", "side": "Acquisition", "shares": 1105.0, "share_price": 15.04, "transaction_value": 16619.2, "fetched_at": "2026-07-20T22:02:08.118352+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-30", "executive": "JAIN, RITA", "executive_title": "Director", "security_type": "Stock Option (Right to Buy)", "side_code": "A", "side": "Acquisition", "shares": 1080.0, "share_price": 15.04, "transaction_value": 16243.2, "fetched_at": "2026-07-20T22:02:08.113247+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-30", "executive": "DOYLE, MITTIE", "executive_title": "Chief Medical Officer", "security_type": "Common Stock", "side_code": "A", "side": "Acquisition", "shares": 1779.0, "share_price": 8.04, "transaction_value": 14303.16, "fetched_at": "2026-07-20T22:02:08.125047+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-30", "executive": "PHILIP, RON M", "executive_title": "Director", "security_type": "Stock Option (Right to Buy)", "side_code": "A", "side": "Acquisition", "shares": 69.0, "share_price": 15.04, "transaction_value": 1037.76, "fetched_at": "2026-07-20T22:02:08.120157+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-30", "executive": "DOYLE, MITTIE", "executive_title": "Chief Medical Officer", "security_type": "Stock Option (Right to Buy)", "side_code": "D", "side": "Disposal", "shares": 2875.0, "share_price": 0.0, "transaction_value": 0.0, "fetched_at": "2026-07-20T22:02:08.121625+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-30", "executive": "DOYLE, MITTIE", "executive_title": "Chief Medical Officer", "security_type": "Stock Option (Right to Buy)", "side_code": "D", "side": "Disposal", "shares": 1779.0, "share_price": 0.0, "transaction_value": 0.0, "fetched_at": "2026-07-20T22:02:08.116247+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-23", "executive": "DOYLE, MITTIE", "executive_title": "Chief Medical Officer", "security_type": "Common Stock", "side_code": "D", "side": "Disposal", "shares": 1450.0, "share_price": 18.0, "transaction_value": 26100.0, "fetched_at": "2026-07-13T21:56:36.837425+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-23", "executive": "DOYLE, MITTIE", "executive_title": "Chief Medical Officer", "security_type": "Common Stock", "side_code": "A", "side": "Acquisition", "shares": 1450.0, "share_price": 8.04, "transaction_value": 11658.0, "fetched_at": "2026-07-13T21:56:36.839001+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-23", "executive": "DOYLE, MITTIE", "executive_title": "Chief Medical Officer", "security_type": "Stock Option (Right to Buy)", "side_code": "D", "side": "Disposal", "shares": 1450.0, "share_price": 0.0, "transaction_value": 0.0, "fetched_at": "2026-07-13T21:56:36.835944+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}, {"symbol": "AVTX", "name": "Avalo Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology", "transaction_date": "2026-06-23", "executive": "PHILIP, RON M", "executive_title": "Director", "security_type": "Stock Option (Right to Buy)", "side_code": "A", "side": "Acquisition", "shares": 40200.0, "share_price": 0.0, "transaction_value": 0.0, "fetched_at": "2026-07-13T21:56:36.834333+00:00", "detail_url": "https://sharemaestro.com/insider-activity/company/avtx/", "research_links": {"chart": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/", "report": "/terminal/6efde503-1bff-4b2c-9181-89799e2e6e18/report/", "factor": "/factors/ticker/6efde503-1bff-4b2c-9181-89799e2e6e18/"}}], "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}